ATC Group: N06AX16 Venlafaxine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N06AX16 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N06 Psychoanaleptics
3 N06A Antidepressants
4 N06AX Other antidepressants
5 N06AX16 Venlafaxine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 100 mg

Active ingredients in N06AX16

Active Ingredient Description
Venlafaxine

Venlafaxine has an antidepressant effect. The mechanism of its action in humans is believed to be associated with its potentiation of neurotransmitter activity in the central nervous system.

Related product monographs

Title Information Source Document Type  
DEPEFEX Prolonged-release capsule Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
EFEXOR XL Prolonged-release capsule, hard Health Products Regulatory Authority (IE) MPI, EU: SmPC
EFFEXOR XR Extended-release capsule FDA, National Drug Code (US) MPI, US: SPL/PLR
MAJOVEN Prolonged-release capsule, hard Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
SUNVENIZ XL Prolonged-release tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
VENLABLUE XL Prolonged-release capsule, hard Health Products Regulatory Authority (IE) MPI, EU: SmPC
VENLOR XR Capsule Web Search MPI, US: SPL/PLR
VENSIR Prolonged release capsule, hard Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
VIEPAX Prolonged-release tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Australia (AU)

Austria (AT)

Canada (CA)

Croatia (HR)

Finland (FI)

France (FR)

Germany (DE)

Israel (IL)

Italy (IT)

Japan (JP)

Mexico (MX)

Netherlands (NL)

New Zealand (NZ)

Singapore (SG)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.